Gossamer Bio to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November.

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251107017321/en/

For Investors and Media
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
[email protected]

Source: Gossamer Bio, Inc.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Drought, Wildfires and Heat Are Hampering Europe’s Energy Transition
• Arnold & Itkin Secures $6.5 Million Verdict for Electrician Seriously Injured at Houston Construction Site